Cargando…
Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine
Variability in response to antiplatelet therapy can be explained in part by pharmacogenomics, particularly of the CYP450 enzyme encoded by CYP2C19. Loss-of-function and gain-of-function variants help explain these interindividual differences. Individuals may carry multiple variants, with linkage dis...
Autores principales: | Brown, Sherry-Ann, Pereira, Naveen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872082/ https://www.ncbi.nlm.nih.gov/pubmed/29385765 http://dx.doi.org/10.3390/jpm8010008 |
Ejemplares similares
-
Pharmacogenomics in the United States Community Pharmacy Setting: The Clopidogrel-CYP2C19 Example
por: Kisor, David F, et al.
Publicado: (2021) -
Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability: Application: Pharmacogenomics
por: Ned, Renée M.
Publicado: (2010) -
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
por: Verma, Shefali Setia, et al.
Publicado: (2020) -
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017) -
Precision medicine: from pharmacogenomics to pharmacoproteomics
por: Chambliss, Allison B., et al.
Publicado: (2016)